Investors sold shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) on strength during trading hours on Tuesday. $133.87 million flowed into the stock on the tick-up and $151.18 million flowed out of the stock on the tick-down, for a money net flow of $17.31 million out of the stock. Of all companies tracked, Tobira Therapeutics had the 0th highest net out-flow for the day. Tobira Therapeutics traded up $34.17 for the day and closed at $38.91

Several research analysts recently weighed in on the stock. Cowen and Company restated a “buy” rating and set a $11.00 price target on shares of Tobira Therapeutics in a research report on Wednesday, August 10th. Cantor Fitzgerald started coverage on shares of Tobira Therapeutics in a research report on Wednesday, July 6th. They set a “buy” rating and a $27.00 price target for the company. Zacks Investment Research cut shares of Tobira Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective (up previously from $22.00) on shares of Tobira Therapeutics in a research note on Saturday, August 13th. Five research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $16.75.

The stock’s 50 day moving average is $5.61 and its 200 day moving average is $8.26. The firm’s market capitalization is $732.33 million.

Tobira Therapeutics (NASDAQ:TBRA) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.08. The firm had revenue of $1.06 million for the quarter. Equities analysts expect that Tobira Therapeutics Inc. will post ($2.65) earnings per share for the current year.

In other news, major shareholder A/S Novo sold 66,814 shares of Tobira Therapeutics stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $13.04, for a total value of $871,254.56. Following the sale, the insider now owns 2,073,022 shares of the company’s stock, valued at $27,032,206.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.20% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. boosted its stake in shares of Tobira Therapeutics by 27.9% in the second quarter. Franklin Resources Inc. now owns 750,000 shares of the biopharmaceutical company’s stock valued at $9,420,000 after buying an additional 163,600 shares during the period. BB Biotech AG bought a new stake in shares of Tobira Therapeutics during the second quarter valued at approximately $5,878,000. Vanguard Group Inc. boosted its stake in shares of Tobira Therapeutics by 6.0% in the second quarter. Vanguard Group Inc. now owns 339,175 shares of the biopharmaceutical company’s stock valued at $4,260,000 after buying an additional 19,125 shares during the period. AXA bought a new stake in shares of Tobira Therapeutics during the second quarter valued at approximately $3,472,000. Finally, BlackRock Fund Advisors boosted its stake in shares of Tobira Therapeutics by 256.8% in the second quarter. BlackRock Fund Advisors now owns 227,775 shares of the biopharmaceutical company’s stock valued at $2,861,000 after buying an additional 163,943 shares during the period. 62.02% of the stock is currently owned by institutional investors and hedge funds.

Tobira Therapeutics Company Profile

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

5 Day Chart for NASDAQ:TBRA

Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.